IDEAYA BIOSCIENCES
IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.
IDEAYA BIOSCIENCES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.ideayabio.com
Total Employee:
101+
Status:
Active
Contact:
(650)491-9600
Total Funding:
226.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
2015-10-01
Current Employees Featured
Yujiro S. Hata CEO @ IDEAYA Biosciences
CEO
2015-06-01
Paul A. Stone Chief Financial Officer & General Counsel @ IDEAYA Biosciences
Chief Financial Officer & General Counsel
2018-01-01
Michael Dillon Chief Scientific Officer & Head of Research @ IDEAYA Biosciences
Chief Scientific Officer & Head of Research
2018-03-01
Mark Lackner Senior Vice President @ IDEAYA Biosciences
Senior Vice President
2018-01-01
Bao Truong Vice President Regulatory Affairs @ IDEAYA Biosciences
Vice President Regulatory Affairs
2018-01-01
Andres Ruiz Briseno Vice President, Head of Business Operations and Investor Relations @ IDEAYA Biosciences
Vice President, Head of Business Operations and Investor Relations
2021-11-01
Julie Patel Vice President Human Resources @ IDEAYA Biosciences
Vice President Human Resources
2020-04-01
Founder
Stock Details
Investors List
5AM Ventures
5AM Ventures investment in Series B - IDEAYA Biosciences
Roche Venture Fund
Roche Venture Fund investment in Series B - IDEAYA Biosciences
Canaan Partners
Canaan Partners investment in Series B - IDEAYA Biosciences
GV
GV investment in Series B - IDEAYA Biosciences
Boxer Capital
Boxer Capital investment in Series B - IDEAYA Biosciences
Perceptive Advisors
Perceptive Advisors investment in Series B - IDEAYA Biosciences
WuXi Healthcare Ventures
WuXi Healthcare Ventures investment in Series B - IDEAYA Biosciences
Biotechnology Value Fund
Biotechnology Value Fund investment in Series B - IDEAYA Biosciences
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - IDEAYA Biosciences
Driehaus Capital Management
Driehaus Capital Management investment in Series B - IDEAYA Biosciences
Key Employee Changes
Official Site Inspections
http://www.ideayabio.com Semrush global rank: 4.7 M Semrush visits lastest month: 2.04 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IDEAYA Biosciences"
IDEAYA Biosciences - Crunchbase Company Profile
Contact Email info@ideayabio.com Phone Number (650)491-9600 IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company …See details»
IDEAYA Biosciences Announces Leadership Updates in Research …
Nov 5, 2019 SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company …See details»
Ideaya Biosciences Org Chart + Executive Team - The Official Board
The organizational chart of Ideaya Biosciences displays its 21 main executives including Yujiro Hata, Michael White and Douglas SnyderSee details»
IDEAYA Biosciences - Overview, News & Similar companies
May 7, 2024 IDEAYA Biosciences contact info: Phone number: (650) 443-6209 Website: www.ideayabio.com What does IDEAYA Biosciences do? Ideaya Biosciences is a …See details»
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial …
Nov 18, 2024 "I am delighted to join IDEAYA to build an industry-leading commercial organization that is well positioned to deliver potential first-in-class precision medicine …See details»
IDEAYA Biosciences - Craft
Oct 29, 2024 IDEAYA Biosciences (IDEAYA) is a developer of molecular therapies. It is an oncology-focused biotechnology company committed to the discovery of breakthrough …See details»
Working At IDEAYA Biosciences: Company Overview and Culture
Www.ideayabio.com. Organization Type. Public. Social Media. IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough …See details»
About – IDEAYA Biosciences
Andres was previously at Pharmacyclics, Inc., (NASDAQ: PCYC) where he helped lead the organization’s finance and operations efforts in support of the successful launch of blockbuster …See details»
Investor Relations | IDEAYA Biosciences - Investor …
Feb 11, 2025 4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a …See details»
IDEAYA Biosciences Announces Participation in Upcoming April …
2 days ago How we use your personal data How we use your information depends on the product and service that you use and your relationship with us.See details»
IDEAYA Biosciences Receives US FDA Breakthrough Therapy …
2 days ago IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today …See details»
News Releases - IDEAYA Bio
SOUTH SAN FRANCISCO, Oct. 18, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the …See details»
IDEAYA Biosciences
Jan 16, 2024 IDEAYA Precision Oncology Drug Discovery Platform & IND Engine. 7. AI/ML & Structure Based Drug Design to Deliver First-in-Class Development CandidatesSee details»
News Releases - ir.ideayabio.com
Mar 3, 2025 SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the …See details»
IDEAYA Biosciences Announces Participation in Upcoming April …
1 day ago SOUTH SAN FRANCISCO, Calif., April 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the …See details»
IDEAYA Biosciences Announces Participation in Upcoming April …
1 day ago 2025 RBCCM Ophthalmology Conference Thursday, April 3 rd, 2025 at 11:30 AM ET. Fireside chat with Yujiro S. Hata, President and Chief Executive Officer and Darrin Beaupre, …See details»
IDEAYA Biosciences Announces Collaboration with ATTMOS to …
Mar 3, 2025 populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging …See details»
IDEAYA Biosciences to Participate in Upcoming February 2025 …
Jan 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the …See details»
IDEAYA Biosciences Receives US FDA Breakthrough Therapy …
2 days ago Designation enables expedited development and priority regulatory review; BTD application was supported by updated clinical data from Ph2 neoadjuvant UM trial that we are …See details»
IDEAYA Biosciences
Nov 11, 2024 The Next Frontier in Precision Medicine Oncology. 4. Leading Functional Genomics and Synthetic Lethality Platform 4. Nature Reviews Genetics, Vol. 18, 2017, Hieter, …See details»